Journal info
|
||
Select Journal
Journals
Acta Virologica Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.67, No.6, p.1400–1408, 2020 |
||
| Title: Objective response of first-line chemotherapy of triple-negative breast cancer translates into survival benefit: an analysis in an independent, prospective clinical trial and a real-world setting | ||
| Author: T. LI, Y. H. ZHU, J. ZHANG, B. Y. WANG, S. ZHANG, L. P. WANG, J. CAO, Z. H. TAO, J. XIE, X. C. HU | ||
| Abstract: This study sought to assess whether the objective response (OR, including complete response and partial response) of first-line chemotherapy can predict overall survival (OS) for patients with metastatic triple-negative breast cancer (mTNBC) in both clinical trial and a real-world setting. The survival predictable parameters were assessed in two independent cohorts, the training cohort of 236 patients as part of a phase 3 trial (CBCSG006, Trial registration number NCT0128762) and the validation cohort of 360 patients from the real-world setting. Univariable and multivariable Cox proportional hazard models were applied to explore associations with progression-free survival and OS in the training cohort and then in the validation cohort. OR (OR vs non-OR, HR, 0.438, P < 0.001) together with Eastern Cooperative Oncology Group (ECOG) performance status, disease-free survival, number of metastatic organ sites and platinum-based chemotherapy used as first-line chemotherapy were observed to be independent prognostic factors for progression-free survival (PFS), and OR (OR vs non-OR, HR, 0.602, P = 0.002) together with ECOG score, disease-free survival, number of metastatic organ sites and previous anthracycline and/or taxane treatment were observed to be independent predictive factors for OS in the training cohort. These predictors were confirmed in the validation cohort. For OR and non-OR group, median OS was 23.72 and 13.83 months in the training cohort (HR, 0.637, P = 0.002), and 21.95 and 13.80 months in the validation cohort (HR, 0.608, P tus with any regimen of first-line chemotherapy in an independent prospective clinical trial and a real-world setting. Therefore, TNBC, not like other subtypes of breast cancer, may be in need of combination chemotherapy or intense chemotherapy to achieve a high response rate for survival. |
||
| Keywords: first-line chemotherapy; metastatic triple-negative breast cancer; objective response; overall survival | ||
| Published online: 13-Jul-2020 | ||
| Year: 2020, Volume: 67, Issue: 6 | Page From: 1400, Page To: 1408 | |
| doi:10.4149/neo_2020_200225N182 |
||
|
|
 download file |
|